Profil
Thomas McCauley is currently Chief Scientific Officer at Stoke Therapeutics, Inc. since 2026.
Formerly, Dr. McCauley was President & Chief Executive Officer at Neptune Biotech, Inc. Chief Scientific Officer at Translate Bio, Inc. from 2016 to 2018.
Chief Scientific Officer at Zikani Therapeutics, Inc. from 2018 to 2019.
Vice President at Shire Pharmaceuticals, Inc. from 2010 to 2016.
Chief Scientific Officer at Omega Therapeutics, Inc. from 2019 to 2024.
Education includes undergraduate studies at Cornell University and a doctorate from The University of Alabama at Birmingham.
Postes actifs de Thomas McCauley
| Sociétés | Poste | Début |
|---|---|---|
| STOKE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 13/07/2026 |
Anciens postes connus de Thomas McCauley
| Sociétés | Poste | Fin |
|---|---|---|
| OMEA THER | Directeur Technique/Scientifique/R&D | 14/08/2024 |
Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens | Corporate Officer/Principal | 01/07/2019 |
| TRANSLATE BIO, INC. | Corporate Officer/Principal | 01/04/2018 |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01/08/2016 |
Formation de Thomas McCauley
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Translate Bio, Inc.
Translate Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage mRNA therapeutics company that develops transformative medicines to treat diseases caused by protein | Health Technology |
Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens | Retail Trade |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
The University of Alabama at Birmingham
The University of Alabama at Birmingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases | Health Technology |
Omega Therapeutics, Inc.
Omega Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for general and rare genetic diseases, immunology, inflammation, oncology and metabolic diseases | Health Technology |
















